376P The impact of T790M mutation status for later-line osimertinib in non-small cell lung cancer patients with progression on frontline epidermal growth factor receptor tyrosine kinase inhibitor

T.Y Jei,C-E Wu,C.T Yang

doi:10.1016/j.annonc.2022.10.414

376P The impact of T790M mutation status for later-line osimertinib in non-small cell lung cancer patients with progression on frontline epidermal growth factor receptor tyrosine kinase inhibitor

T.Y Jei, C-E Wu + Show 1 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.414

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital

#Factor Receptor Tyrosine Kinase Inhibitor #Growth Factor Receptor Tyrosine Kinase + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) which was designed to overcome acquired T790M resistance mutation. This study aimed to evaluate advanced non-small cell lung cancer (NSCLC) patient after first- and second- generation EGFR-TKIs followed by later line osimertinib treatment.

Full Text